| アブストラクト | INTRODUCTION: Until extended half-life (EHL) factor IX (FIX) concentrates became available in Japan in 2010, patients with hemophilia B received intravenous FIX replacement therapy with standard half-life (SHL) FIX concentrates. PURPOSE: To investigate the amount of factor dispensed and the associated medical expenditures for the treatment of hemophilia B in the real-world clinical setting in Japan. METHODS: This retrospective study comprised patients with hemophilia B (N=197) who had filled prescriptions for FIX concentrates reported in Japan's Medical Data Vision database from 2015 to 2019. Patients were included if they had 2 or more prescriptions for the same FIX concentrates within the first 6 months of the study period and the interval between prescriptions was at least 2 weeks. RESULTS: Since 2015, there was a decrease in the proportion of patients using SHL FIX concentrates and a corresponding increase in international units of dispensed EHL FIX concentrates. Median annualized dispensed dosages (IU/kg body weight) of EHL FIX concentrates were lower than for SHL concentrates for outpatient use only. Annual total health care expenditures per patient and annual expenditures for prescribed FIX concentrates increased each year during the study period. Following a switch from an SHL to an EHL concentrate, the median amount of prescribed FIX concentrate decreased slightly, although median total health care expenditures and FIX concentrate expenditures increased. CONCLUSION: In the real-world setting in Japan, medical expenditures and the proportion of patients prescribed EHL FIX concentrates for the treatment of hemophilia B have increased. |
|---|
| ジャーナル名 | Journal of blood medicine |
|---|
| Pubmed追加日 | 2023/12/25 |
|---|
| 投稿者 | Fukutake, Katsuyuki; Togo, Kanae; Xu, Linghua; Markson, Leona E; Alvir, Jose Maria Jimenez; Winburn, Ian; Karumori, Toshiyuki |
|---|
| 組織名 | Laboratory Medicine, Tokyo Medical University, Shinjuku, Tokyo, Japan.;Department of Blood Coagulation Diseases, Ogikubo Hospital, Suginami, Tokyo,;Japan.;Pfizer Japan Inc, Shibuya-ku, Tokyo, Japan.;Pfizer Inc, Collegeville, PA, USA.;Pfizer Inc, New York, NY, USA.;Pfizer Ltd, Surrey, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38143791/ |
|---|
